Lifecore Biomedical Stock Guidance | NASDAQ:LFCR

Comments

Lifecore Biomedical Inc Stock Guidance

LFCRNASDAQ

Trade with Public

$5.20

0.265.26%

At close: Apr 14, 5:00 PM EST

$5.30

0.11.92%

After Hours: 4:52 PM EST

Overview News Earnings OptionsGuidanceAnalyst Ratings Insider Trades Short Interest Stock Report

Lifecore Biomedical (LFCR) last issued guidance on March 16, 2026 for fiscal year 2026. The company guided revenue in the range of $120.00M - $125.00M for the period.

Compared to prior guidance, Lifecore Biomedical lowered its revenue forecast from a prior range of $126.00M - $130.00M.

Lifecore Biomedical has issued 5 guidance updates between April 1, 2024 and March 16, 2026. During this period, the company lowered its outlook 1 time, signaling management's revised expectations.

Latest Guidance Date

Mar 16, 2026

Guidance Period

Full Year 2026

Revenue Guidance Range

$120.00M - $125.00M

Lifecore Biomedical Guidance History

Review all historical guidance issued by Lifecore Biomedical, including EPS and revenue forecasts across quarterly and annual periods.

Loading calendar...

FAQ

What is the most recent guidance for Lifecore Biomedical (LFCR)?

The most recent guidance for Lifecore Biomedical (LFCR) was reported on March 16, 2026 for the fiscal year 2026. Lifecore Biomedical forecasted revenue between $120.00M and $125.00M for the period.

What revenue range did Lifecore Biomedical (LFCR) guide for?

Lifecore Biomedical (LFCR) guided revenue in the range of $120.00M to $125.00M for the fiscal year 2026.

Did Lifecore Biomedical (LFCR) raise or lower guidance?

Lifecore Biomedical (LFCR) lowered its revenue guidance from a prior range of $126.00M - $130.00M to $120.00M - $125.00M for the fiscal year 2026.

When did Lifecore Biomedical (LFCR) last issue guidance?

Lifecore Biomedical (LFCR) last issued guidance on March 16, 2026 for the fiscal year 2026.

People Also Watch

Harvard Bioscience Inc

Cytek Biosciences Inc

Champions Oncology Inc

NASDAQ:CSBR

$5.79

1.04%